Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 8;72(7):1247-1250.
doi: 10.1093/cid/ciaa879.

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Boghuma K Titanji  1 , Monica M Farley  1   2 , Ashish Mehta  3   4 , Randi Connor-Schuler  4 , Abeer Moanna  1   2 , Sushma K Cribbs  3   4 , Jesse O'Shea  1 , Kathryn DeSilva  2 , Bonnie Chan  2 , Alex Edwards  5 , Christina Gavegnano  6 , Raymond F Schinazi  7 , Vincent C Marconi  1   2   5   7
Affiliations

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Boghuma K Titanji et al. Clin Infect Dis. .

Abstract

Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.

Keywords: COVID-19; baricitinib; hyper-inflammation.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Body temperature, C-reactive protein (CRP), ESR, IL-6, and survival of patients with moderate to severe coronavirus disease 2019 treated with baricitinib. A, Highest recorded body temperature on day 1 of treatment with baricitinib (red dots) compared with day 5 of therapy (blue dots); temperature significantly decreased (P < .0001) and normalized for 13/15 patients. B, CRP levels before, during, and after baricitinib treatment. Levels were significantly lower post-treatment compared with pretreatment (P < .01). C, ESR levels before and after baricitinib treatment. D, Pretreatment IL-6 levels for all patients in the cohort. E, Kaplan-Meier curve showing time to recovery after baricitinib initiation with death right-censored. Abbreviations: ESR, erythrocyte sedimentation rate; IL, interleukin; ns, not significant; Pt, patient.*p < .05, ***p < .0005.
See this image and copyright information in PMC

Comment in

References

    1. World Health Organization. Coronavirus disease 2019—situation report number 148. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/2.... Accessed 17 June 2020.
    1. Mehta P, McAuley DF, Brown M, et al. ; HLH Across Speciality Collaboration, UK . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033–4. - PMC - PubMed
    1. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46:846–8. - PMC - PubMed
    1. Richardson P, Griffin I, Tucker C, et al. . Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395:e30–1. - PMC - PubMed
    1. Stebbing J, Phelan A, Griffin I, et al. . COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20:400–2. - PMC - PubMed